SCHEMBL17005348

SCHEMBL17005348

O=C(O)[C@@H]1CN(C(=O)O)C[C@H](COCc2ccccc2)O1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
AGTR2 P50052 1/20 0.41
DRD1 P21728 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HRH4 Q9H3N8 4/20 0.38
HRH3 Q9Y5N1 4/20 0.38
GRM5 P41594 1/20 0.38
PTPN1 P18031 2/20 0.38
CDC25B P30305 1/20 0.37
NAAA Q02083 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSK P43235 1/20 0.37
CYP2C19 P33261 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17188998 1.00 LMNA (0.44) LMNAAGTR2DRD1SMN1; SMN2NPC1
SCHEMBL19181699 1.00 LMNA (0.44) LMNAAGTR2DRD1SMN1; SMN2NPC1
SCHEMBL17005434 0.87 LMNA (0.40) LMNAAGTR2DRD1L3MBTL1HRH4
SCHEMBL3128357 0.87 LMNA (0.46) LMNAAGTR2DRD1SMN1; SMN2L3MBTL1
SCHEMBL2806983 0.87 LMNA (0.46) LMNAAGTR2DRD1SMN1; SMN2L3MBTL1
SCHEMBL17005427 0.87 LMNA (0.46) LMNAAGTR2DRD1SMN1; SMN2L3MBTL1
SCHEMBL17189006 0.86 LMNA (0.45) LMNAAGTR2DRD1L3MBTL1HRH4
SCHEMBL2811260 0.85 GAA (0.41) LMNASMN1; SMN2PTPN1
SCHEMBL17005366 0.85 GAA (0.41) LMNASMN1; SMN2PTPN1
SCHEMBL23249940 0.85 SMN1; SMN2 (0.45) LMNASMN1; SMN2NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2933248-B1 NOVEL RENIN INHIBITOR MITSUBISHI TANABE PHARMA CORP (JP) 2018-01-31 EP disclosed
US-9556159-B2 Renin inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-31 US disclosed
EP-2933248-A1 NOVEL RENIN INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2015-10-21 EP disclosed
US-20150232459-A1 NOVEL RENIN INHIBITOR SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232459-A1 NOVEL RENIN INHIBITOR REN, AGTR1, ACE LMNA 3348/4885AGTR2 4/4885DRD1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.